Literature DB >> 17604321

Macrolide-resistant Staphylococcus aureus colonization in cystic fibrosis patients: is there transmission to household contacts?

Gerdien A Tramper-Stranders1, Cornelis K van der Ent, Susan A M Gerritsen, André Fleer, Jan L L Kimpen, Tom F W Wolfs.   

Abstract

OBJECTIVES: Patients with cystic fibrosis (CF) are frequently colonized by macrolide-resistant Staphylococcus aureus, a result of maintenance macrolide therapy. As transmission of S. aureus between household contacts is common, we examined the prevalence of macrolide-resistant S. aureus colonization in CF patients on maintenance azithromycin therapy and their household contacts and compared this with the S. aureus macrolide resistance prevalence in the community. PATIENTS AND METHODS: Sixty-five CF patients on maintenance macrolide therapy and 194 household contacts were screened for S. aureus colonization by culturing sputa, cough swabs and nasal swabs. Resistance to macrolide, lincosamide and methicillin was determined by disc diffusion tests. The prevalence of macrolide-resistant S. aureus colonization in both groups was compared with figures from a nationwide study into S. aureus carriership and resistance. To assess possible transmission, genotyping of S. aureus was performed using the spa-typing method.
RESULTS: Macrolide resistance among CF patients with S. aureus colonization was 69.6%; 75% of these isolates displayed lincosamide resistance too. Among household contacts, macrolide resistance prevalence did not differ significantly from resistance prevalence in the community (9.6% versus 6.3%; P = 0.358). No methicillin resistance was observed. No identical (macrolide-resistant and -susceptible) S. aureus genotypes were observed between CF patients and their household contacts except for one household, suggesting a probable transmission.
CONCLUSIONS: No significant increase in macrolide-resistant S. aureus colonization was observed among household contacts of CF patients on long-term azithromycin therapy. Transmission of macrolide-resistant S. aureus could not be proved by genotyping in the majority of households.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17604321     DOI: 10.1093/jac/dkm235

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  4 in total

1.  Methicillin-resistant Staphylococcus aureus nasal colonization in a department of pediatrics: a cross-sectional study.

Authors:  Francesco Gesualdo; Manuela Onori; Dafne Bongiorno; Floriana Campanile; Emanuela Carloni; Livia Mancinelli; Cristina Russo; Alberto Villani; Diletta Valentini; Massimiliano Raponi; Alberto E Tozzi; Stefania Stefani
Journal:  Ital J Pediatr       Date:  2014-01-10       Impact factor: 2.638

2.  The impact of long-term azithromycin on antibiotic resistance in HIV-associated chronic lung disease.

Authors:  Regina E Abotsi; Mark P Nicol; Grace McHugh; Victoria Simms; Andrea M Rehman; Charmaine Barthus; Lucky G Ngwira; Brenda Kwambana-Adams; Robert S Heyderman; Jon Ø Odland; Rashida A Ferrand; Felix S Dube
Journal:  ERJ Open Res       Date:  2021-02-07

3.  Prevention of bacterial infections in the newborn by pre-delivery administration of azithromycin: Study protocol of a randomized efficacy trial.

Authors:  Anna Roca; Claire Oluwalana; Bully Camara; Abdoulie Bojang; Sarah Burr; Timothy M E Davis; Robin Bailey; Beate Kampmann; Jenny Mueller; Christian Bottomley; Umberto D'Alessandro
Journal:  BMC Pregnancy Childbirth       Date:  2015-11-19       Impact factor: 3.007

4.  Longitudinal nasopharyngeal carriage and antibiotic resistance of respiratory bacteria in indigenous Australian and Alaska native children with bronchiectasis.

Authors:  Kim M Hare; Rosalyn J Singleton; Keith Grimwood; Patricia C Valery; Allen C Cheng; Peter S Morris; Amanda J Leach; Heidi C Smith-Vaughan; Mark Chatfield; Greg Redding; Alisa L Reasonover; Gabrielle B McCallum; Lori Chikoyak; Malcolm I McDonald; Ngiare Brown; Paul J Torzillo; Anne B Chang
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.